Cancer and Thrombosis: New Treatments, New Challenges
The direct-acting oral anticoagulant (DOAC) has become an alternative to low-molecular-weight heparin (LMWH) for treatment and prophylaxis of venous thromboembolism (VTE) in cancer patients. The clinicians are, however, faced with difficult decisions regarding DOAC treatment: Which patients cannot u...
| Հիմնական հեղինակ: | |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
MDPI AG
2021-06-01
|
| Շարք: | Medical Sciences |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.mdpi.com/2076-3271/9/2/41 |